A higher percentage of patients treated with an experimental Pfizer Inc drug for osteoporosis died during a clinical trial compared with a placebo, U.S. drug reviewers said in an analysis released on Thursday.
The higher proportion of deaths through five years was statistically significant only for the lowest dose of the drug called Fablyn, said Food and Drug Administration reviewers. More patients given Fablyn, which was co-developed with Ligand Pharmaceuticals Inc, also developed blood clots.
More...
FDA staff note deaths in Pfizer bone drug study
Donald Trump has selected Erica Schwartz to lead the Centers for Disease Control and Prevention (CDC),...
The Supreme Court sided with a Christian counselor on Tuesday in her free speech challenge to...
More than 3.1 million bottles of eye drops sold at major retailers, including Walgreens and CVS,...
The abortion rate is holding steady in the US despite total and partial bans in some...
